Zoetis Inc. today announced that the European Commission has granted an extended duration of immunity against Mycoplasma hyopneumoniae (MH) for Suvaxyn® Circo+MH RTU combination vaccine. Suvaxyn Circo+MH RTU is the first and only combination vaccine to have demonstrated 23 weeks’ duration of immunity for both MH and porcine circovirus-type 2 (PCV2).
With Suvaxyn Circo+MH RTU, European swine veterinarians and swine producers now can rely on even longer protection against MH. A recent study1,2 reviewed by the European Medicines Agency and included in the regulatory variation procedure approved by the European Commission demonstrated the vaccine was effective in reducing lung lesions caused by MH and demonstrated at least 23 weeks duration of immunity against the pathogen.
“Enzootic pneumonia or mycoplasmal pneumonia caused by MH remains a highly prevalent and costly disease for swine producers, and vaccination is a key part of an effective, comprehensive approach to controlling MH and secondary infections,” said Prof. Paolo Martelli, at the University of Parma in Italy.
“We welcome the extension of the duration of immunity for Suvaxyn Circo+MH RTU as great news for European veterinarians and pig producers. It demonstrates that our vaccine can help growing pigs, providing the longest protection against both PCV2 and MH in a combination vaccine: one dose from three weeks of age that lasts all the way to market. This is a prime example of our continuous improvements in the solutions we offer to our customers,” said Alvaro Aldaz, Director, Commercial Development and Lifecycle Innovation, Swine at Zoetis.
1. Allison J. et al. Efficacy of a PCV2 and Mycoplasma hyopneumoniae vaccine (Fostera PCV MH / Suvaxyn Circo+MH RTU) in protecting from M. hyo challenge either 16 or 23 weeks post-vaccination 24th IPVS Congress, Dublin 2016.
2. Zoetis study on file B824R-US-15-505
July 6, 2017 - Zoetis